Novo Nordisk A/S
NVOToday
-1.52%
5 Days
-2.99%
1 Month
-4.80%
6 Months
-35.17%
Year to Date
-28.60%
1 Year
-50.64%
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2026-03-25Key Insights
Novo Nordisk A/S's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 49.95.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Support & Resistance
Score Analysis
Media Coverage
Novo Nordisk A/S Highlights
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Analyst Rating
Novo Nordisk A/S News
Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market
TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.
Novo Nordisk Shares Plunge, Eli Lilly Zepbound Multi-Dose Approved, Weight-Loss Drug Throne Changing Hands?
TradingKey - Amid the ongoing surge in the global weight-loss drug market, Eli Lilly (LLY) announced that its Zepbound four-dose KwikPen device has received U.S. FDA approval. Following the announcement, the company's share price rose 4.86% in a single day, further strengthening market expectations
What to Expect From Eli Lilly in 2026? Is LLY Stock a Good Buy Now?
The company’s main goal and focus in 2026 will be to maintain its leadership position in weight management, whilst expanding further into additional therapeutic areas, so that revenue growth will not be dependent on a singular product. It is expected that Eli Lilly’s stocks will serve as a predictor
Novo Nordisk 2026: Will the Ozempic Makers Benefit From the Strong Demand for Oral Wegovy?
Who owns Ozempic? Novo Nordisk (NVO) does, and that simple fact places the firm at the heart of the global discussion around GLP-1 drugs. But the story today for the market is another one.
Novo Nordisk’s First Oral Weight-Loss Drug Wins FDA Approval — How Long Can Eli Lilly Hold Its Lead?
TradingKey - On Monday, December 22, The U.S. Food and Drug Administration (FDA) officially approved the oral tablet version of Novo Nordisk's Wegovy injection, making it the world's first approved oral GLP-1 weight-loss medication.
Novo Nordisk (NVO) : From Market Darling to Selloff Target — Should You Buy the Dip?
TradingKey - We've recently observed that,Novo Nordisk A/S, impacted by intensifying competition in weight-loss drugs (such as from U.S.Eli Lilly and Company) and weaker-than-expected earnings reports, has seen its stock price continually decline, falling over 70% from its peak of 143.54.
Financial Indicators
EPS
Total revenue
Novo Nordisk A/S Info
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Related Instruments
Popular Symbols
